In this episode of Denatured, you’ll listen to Christina Takke, managing partner at V-Bio Ventures and Mariette van der Velden-Roesink, founding partner at Curie Capital. We examine why Benelux delivers world‑class science yet remains an investment patchwork, and what it will take to knit the region into a truly unified biotech investment corridor.Host<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/jennifersmithparker/" target="_blank">⁠Jennifer C. Smith-Parker</a>, Director of Insights, BioSpaceGuests<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christina-takke-a93200/" target="_blank">Christina Takke</a>, Managing Partner, V-Bio Ventures<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/mlroesink/" target="_blank">Mariette van der Velden-Roesink</a>, Founding Partner, Curie CapitalDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.